Addex Therapeutics Ltd (ADXN)
8.79
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
8.78
-0.01
(-0.11%)
After-Hours: 20:00
Addex Therapeutics SG&A Expense (Quarterly): 1.922M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.922M |
| September 30, 2023 | 1.982M |
| June 30, 2023 | 2.169M |
| March 31, 2023 | 1.945M |
| December 31, 2022 | 2.677M |
| September 30, 2022 | 2.475M |
| June 30, 2022 | 2.178M |
| March 31, 2022 | 3.300M |
| December 31, 2021 | 1.940M |
| September 30, 2021 | 2.237M |
| Date | Value |
|---|---|
| June 30, 2021 | 2.028M |
| March 31, 2021 | 1.462M |
| December 31, 2020 | 1.386M |
| September 30, 2020 | 1.345M |
| June 30, 2020 | 1.647M |
| March 31, 2020 | 1.728M |
| December 31, 2019 | -0.763M |
| September 30, 2019 | 1.793M |
| June 30, 2019 | 1.475M |
| March 31, 2019 | 1.504M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
-0.763M
Minimum
Dec 2019
3.300M
Maximum
Mar 2022
1.838M
Average
1.940M
Median
Dec 2021
SG&A Expense (Quarterly) Benchmarks
| AC Immune SA | 5.688M |
| CRISPR Therapeutics AG | 17.95M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 5.036M |
| MoonLake Immunotherapeutics | 6.806M |